纳武单抗在非小细胞肺癌患者管理中的新兴作用：当前数据与未来展望
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.
作者信息
Feld Emily, Horn Leora
机构信息
Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Onco Targets Ther. 2017 Jul 24;10:3697-3708. doi: 10.2147/OTT.S97903. eCollection 2017.
Abstract
Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of the first immune-checkpoint inhibitors to demonstrate clinical activity in patients with NSCLC, and is currently approved in the US for treatment of patients with advanced squamous and nonsquamous NSCLC who have progressed on or after platinum-based chemotherapy. This review provides an update on nivolumab's pharmacology, safety, and efficacy, as established by the CheckMate trials. We also discuss specific applications and strategies for the use of nivolumab in NSCLC patients, as well as predictive biomarkers and their role in treatment selection.
摘要
免疫检查点抑制剂已成为治疗非小细胞肺癌（NSCLC）患者的重要疗法。与细胞毒性化疗相比，近期临床试验显示这些药物在疗效和毒性方面有令人鼓舞的结果。纳武单抗是最早在NSCLC患者中显示临床活性的免疫检查点抑制剂之一，目前在美国被批准用于治疗铂类化疗后进展的晚期鳞状和非鳞状NSCLC患者。本综述根据CheckMate试验对纳武单抗的药理学、安全性和疗效进行了更新。我们还讨论了纳武单抗在NSCLC患者中的具体应用和策略，以及预测性生物标志物及其在治疗选择中的作用。
相似文献
1
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.纳武单抗在非小细胞肺癌患者管理中的新兴作用：当前数据与未来展望
Onco Targets Ther. 2017 Jul 24;10:3697-3708. doi: 10.2147/OTT.S97903. eCollection 2017.
2
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与含或不含贝伐珠单抗的一线含铂化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2.
3
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
4
Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.美国一线治疗晚期非小细胞肺癌相关的不良事件成本：免疫检查点抑制剂临床试验分析。
J Manag Care Spec Pharm. 2023 Sep;29(9):1054-1064. doi: 10.18553/jmcp.2023.29.9.1054.
5
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.CheckMate 017 和 057 随机、III 期临床试验的 5 年结果：纳武利尤单抗对比多西他赛用于先前治疗的非小细胞肺癌。
J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15.
6
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.纳武利尤单抗对比多西他赛用于治疗既往接受过治疗的晚期非小细胞肺癌（CheckMate 017 和 CheckMate 057）：3 年更新结果及肝转移患者的结局。
Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.
7
Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.信迪利单抗联合化疗用于晚期或转移性非鳞状非小细胞肺癌的一线治疗：网络荟萃分析。
Immunotherapy. 2023 Mar;15(4):293-309. doi: 10.2217/imt-2022-0252. Epub 2023 Feb 7.
8
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).纳武利尤单抗对比多西他赛用于既往接受过治疗的晚期非小细胞肺癌患者：两项随机、开放标签、III期试验（CheckMate 017和CheckMate 057）的两年结果
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.
9
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.纳武利尤单抗：在晚期非鳞状非小细胞肺癌中的应用评价。
Drugs. 2016 Jun;76(9):969-78. doi: 10.1007/s40265-016-0589-9.
10
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.纳武利尤单抗联合化疗一线治疗转移性非小细胞肺癌：CheckMate 227 部分 2 期研究的结果。
ESMO Open. 2023 Dec;8(6):102065. doi: 10.1016/j.esmoop.2023.102065. Epub 2023 Nov 20.
引用本文的文献
1
An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations.一种信息学桥梁，可提高抗癌药物组合的 I 期临床试验的设计和效率。
Cancer Res Commun. 2022 Sep 6;2(9):929-936. doi: 10.1158/2767-9764.CRC-22-0160. eCollection 2022 Sep.
2
Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).顺铂和依托泊苷联合胸部放疗后使用纳武单抗或安慰剂治疗局部晚期非小细胞肺癌的试验（RTOG 3505）评论
J Thorac Dis. 2017 Oct;9(10):3525-3528. doi: 10.21037/jtd.2017.09.12.
3
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.免疫疗法“冲击”：一组程序性死亡受体配体1（PD-L1）表达为100%且帕博利珠单抗一线治疗的病例系列
Respir Med Case Rep. 2017 Aug 29;22:197-202. doi: 10.1016/j.rmcr.2017.08.017. eCollection 2017.
本文引用的文献
1
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.不同程序性死亡配体-1 诊断检测试剂用于非小细胞肺癌不同蛋白表达截断值时的一致性。
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591. doi: 10.1158/1078-0432.CCR-16-2375. Epub 2017 Jan 10.
2
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
3
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.肺癌配对原发灶与脑转移灶之间程序性细胞死亡配体1表达和淋巴细胞肿瘤浸润的时空不一致性。
Ann Oncol. 2016 Oct;27(10):1953-8. doi: 10.1093/annonc/mdw289. Epub 2016 Aug 8.
4
Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.抗程序性细胞死亡蛋白-1 治疗相关暴发性 1 型糖尿病。
J Diabetes Investig. 2016 Nov;7(6):915-918. doi: 10.1111/jdi.12531. Epub 2016 May 31.
5
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.PD-L1表达作为非小细胞肺癌患者的预测性生物标志物：一项汇总分析。
Oncotarget. 2016 Apr 12;7(15):19738-47. doi: 10.18632/oncotarget.7582.
6
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.通过免疫组织化学评估程序性死亡受体配体1（PD-L1）状态：肺癌患者治疗策略面临的挑战与前景
Virchows Arch. 2016 May;468(5):511-25. doi: 10.1007/s00428-016-1910-4. Epub 2016 Feb 25.
7
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.转移性鳞状细胞非小细胞肺癌（NSCLC）：免疫疗法打破药物治疗模式
Drugs Context. 2015 Oct 14;4:212289. doi: 10.7573/dic.212289. eCollection 2015.
8
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.非小细胞肺癌中 PD-L1 表达异质性的定量评估。
JAMA Oncol. 2016 Jan;2(1):46-54. doi: 10.1001/jamaoncol.2015.3638.
9
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.手术切除标本与 NSCLC 患者匹配活检的 PD-L1 状态的比较研究显示出主要的不一致性：这可能是抗 PD-L1 治疗策略的一个问题。
Ann Oncol. 2016 Jan;27(1):147-53. doi: 10.1093/annonc/mdv489. Epub 2015 Oct 19.
10
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.抑制免疫检查点和血管内皮生长因子联合治疗转移性黑色素瘤：原理、临床前证据及初步临床数据概述
Front Oncol. 2015 Sep 22;5:202. doi: 10.3389/fonc.2015.00202. eCollection 2015.
Zotero 插件